A Coronary-Friendly Device Mitigating Risk of Coronary Obstruction in Transcatheter Aortic Valve Replacement
Yuntao Lu,Minyan Yin,Ye Yang,Wenshuo Wang,Lili Dong,Xue Yang,Chunsheng Wang,Xiaolin Wang,Jinmiao Chen,Lai Wei
DOI: https://doi.org/10.2147/cia.s467594
IF: 3.829
2024-09-26
Clinical Interventions in Aging
Abstract:Yuntao Lu, 1, 2, &ast Minyan Yin, 3, 4, &ast Ye Yang, 1, 2, &ast Wenshuo Wang, 1, 2 Lili Dong, 5 Xue Yang, 3, 4 Chunsheng Wang, 1, 2 Xiaolin Wang, 3, 4 Jinmiao Chen, 1, 2 Lai Wei 1, 2 1 Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Shanghai Engineering Research Center of Heart Valve, Shanghai, People's Republic of China; 3 Shanghai Institute of Medical Imaging, Shanghai, People's Republic of China; 4 Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 5 Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lai Wei; Jinmiao Chen, Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Tel +86 021 64041990, Email ; Purpose: Transcatheter aortic valve replacement (TAVR) induced coronary artery obstruction (CAO) is a rare but devastating complication. Current preventive strategies need additional procedures and may be associated with adverse events. This study aimed to evaluate the early safety and efficacy of stand-alone TAVR using the J-Valve (Jianshi JieCheng Medical Technology Co. Ltd, Shanghai, China) in patients at potential high risk for CAO. Patients and Methods: CAO was defined as coronary ostia obstruction requiring intervention. Patients at potential high risk for CAO were identified retrospectively from 673 consecutive patients who underwent TAVR from January 2015 to July 2021 at Zhongshan Hospital, Fudan University. Procedural results and early outcomes were evaluated according to Valve Academic Research Consortium-3 definitions. Results: A total of 20 consecutive patients (age 72 ± 9 years; 85% female;) were included. The Society of Thoracic Surgeons-Predicted Risk of Mortality was 5% (interquartile range, 4 to 10%). All patients (100%) had at least 2 classical risk factors for CAO by pre-procedural computed tomography analysis, and 90% patients had native aortic valve diseases. TAVR was successful in 95% of cases, with only 1 patient requiring second device implantation. Early safety at 30 days was achieved in all cases without death. All patients were free from CAO, stroke or emergency reintervention. Post-procedural mean aortic valve gradient was 7 (interquartile range, 4, 12) mmHg, and none/trace or mild aortic regurgitation was present in all patients. Conclusion: Stand-alone TAVR using the J-Valve may mitigate the risk of TAVR-induced CAO. Keywords: TAVR, coronary artery obstruction, aortic regurgitation, aortic stenosis, structural heart disease Graphical Coronary artery obstruction (CAO) in transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve implantation (TAVIV) is caused by the displacement of the diseased leaflet (native valve or bioprostheses) toward the coronary ostia and/or sinotubular junction (STJ) by the implanted transcatheter heart valve (THV). It is a rare complication (incidence < 1% in TAVR, ≈3% in TAVIV); however, it is likely to be underestimated, as many patients are excluded from TAVR due to potential CAO risk. 1–3 TAVR-induced CAO is devastating because the 30-day mortality rate is 52.9%. 3 Risk factors for CAO during TAVR include but not limited to female, low-lying coronary ostia, narrow sinus of Valsalva, bioprostheses with externally mounted leaflets and stentless surgical valve. 1,3 Surgical aortic valve replacement is the standard treatment for patients at high risk of TAVR-induced CAO. Additional interventions may be useful, including coronary protection with pre-emptive wiring and stenting (regular stent and chimney technique) 4,5 and bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA). 6,7 Although both techniques have the potential to prevent CAO in selected patients, they are also associated with the risk of serious complications, such as stent failure and stroke. 8 J-Valve (Jianshi JieCheng Medical Technology Co, Ltd, Shanghai, China) is a self-expanding, low-profile transapical heart valve. Previous studies have reported the feasibility of the J-Valve for treatment in aortic regurgitation and/or stenosis, and the mid-term outcomes were promising. 9–11 J-Valve was reported to use as a new opti -Abstract Truncated-
geriatrics & gerontology,gerontology